Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
+2.16 (+1.28%)
4:47:31 PM EDT: $170.65 +0.11 (+0.07%)
Products, Strategic Combinations

Kaleido Biosciences Announces Expansion Of Collaboration With Janssen To Explore Potential Of Microbiome Metabolic Therapies (Mmt) To Prevent Childhood-Onset Of Atopic, Immune And Metabolic Cond

Published: 12/06/2021 14:14 GMT
Johnson & Johnson (JNJ) - Kaleido Biosciences Announces Expansion of Collaboration With Janssen to Explore Potential of Microbiome Metabolic Therapies (mmt™) to Prevent Childhood-onset of Atopic, Immune and Metabolic Conditions.
Kaleido Biosciences Inc - Existing Agreement With Janssen Has Been Extended.
Kaleido Biosciences Inc - Janssen Will Fund Additional Costs Associated With Expanded Scope of Collaboration.